Millions of Nigerians no longer are at risk of a disfiguring tropical disease, thanks to a pioneering partnership between the Federal Ministry of Health and The Carter Center. The partners have eliminated lymphatic filariasis as a public health problem in two states in Nigeria, Africa’s most populous country and the seventh-largest in the world.
“This is a great day for the people of Plateau and Nasarawa states, and all of Nigeria,” said Dr. Yisa A. Saka, director of Neglected Tropical Disease Programs with Nigeria’s Federal Ministry of Health. “Together with The Carter Center and our many other valuable partners, we are gaining the advantage over a terrible disease that has plagued good people for far too long.”
With over 120 million people at risk nationwide, Nigeria is the most endemic country in Africa for the parasitic disease and second most endemic in the world, behind only India.
“Eliminating lymphatic filariasis as a public health problem in Plateau and Nasarawa states is a significant achievement that challenges everyone to broaden their appreciation of what is possible,” said Dr. Frank O. Richards Jr., director of the Carter Center’s Lymphatic Filariasis Elimination Program. “Success in these two states not only protects the 7 million people who live there, but it also sets a pattern for similar success throughout the rest of Nigeria, as well as in other highly endemic countries.”
Lymphatic filariasis, or LF, is caused by parasitic worms transmitted from infected persons to others by mosquito bites. The worms impair the lymphatic system, resulting in periodic fevers, fluid collection in the tissues (most commonly the limbs and genitalia), and severe swelling often known as elephantiasis. In addition to pain and reduced mobility, people disfigured by LF often experience crushing social stigma and chronic economic hardship that has a ripple effect across entire families and communities through lost productivity.
To tackle the disease in the two states’ 30 local government areas, community-selected volunteers mobilized to educate their neighbors and annually distributed a combination of free medications — albendazole, donated by GSK, and Mectizan®, donated by Merck & Co., Inc., which also is used in the fight against another parasitic disease, river blindness. In Plateau and Nasarawa alone, more than 36 million drug treatments for lymphatic filariasis were delivered between 2000 and 2012.
Insecticide-treated bed nets to prevent mosquito bites are an additional tool to fight LF, especially for those who are not eligible to take the medications, such as children under 5 years old and pregnant women. The Carter Center assisted the national program and community health workers in the distribution and proper use of bed nets to protect against the night-biting Anopheles mosquitoes that can carry both LF and malaria. In Plateau and Nasarawa states, Clarke Cares Foundation/Clarke Mosquito Control donated more than 140,000 bed nets.
“The community-directed distributors are the real heroes here,” Richards said. “These are regular people stepping up to do the heavy lifting to improve the lives of their families and neighbors. Their commitment and diligence accelerate health programs’ success.”
Work over the years included continuously monitoring the effectiveness of the program until it reduced the infection level in Plateau and Nasarawa states to the point where community-wide drug treatment could be discontinued in 2012. The program then moved into its next phase, called post-treatment surveillance, with financial support from the ENVISION Project, based at RTI International and funded by the U.S. Agency for International Development. A series of rigorous epidemiological surveys have been conducted throughout the two states to confirm transmission has been interrupted. Researchers examine finger-prick blood samples from children for evidence of the parasites in their blood. If transmission has been interrupted, those children’s tests should come back negative, said Dr. Gregory Noland, health program epidemiologist at The Carter Center.
“Over the past two years, we have tested more than 14,000 children ages 6 and 7 throughout the two-state area, and not one of them was found to be infected,” Noland said. “This definitive outcome is a testament to the foresight of those who launched the program, believing that elimination was possible in one of the world’s most endemic countries. In human terms, these children will never have to worry about being disabled by lymphatic filariasis.”
Continued surveillance and maximizing bed-net coverage are still required to guard against importation of the infection from surrounding endemic states until Nigeria achieves elimination nationwide, Noland cautioned.
Meanwhile, those already afflicted with elephantiasis continue to need care and support to prevent further disability. Under the guidance of health worker John Umaru, lymphatic filariasis patients known as the Hope Group meet regularly at The Carter Center’s office in Jos, the capital of Plateau state. Hope Group members — younger and older, male and female — learn how to care for the vulnerable skin of their swollen limbs and, just as important, have the opportunity to socialize, express themselves, and give and receive emotional support.
“It’s great that future generations will never know this kind of suffering,” Umaru said. “This unique group helps people understand that although there is no cure for their legs, they don’t have to get worse, and there is hope for living fulfilling and productive lives.”
- Monkeypox: 31 suspected cases reported in seven Nigerian states, public asked to ‘remain calm’
- Plague death toll now 57, 10 million Euros needed in outbreak battle
- Namibia anthrax update: 20 buffalo killed in outbreak
- Seychelles: Traveler to Madagascar tests plague positive, Hospital to set up isolation unit
- Measles outbreak in Bong County, Liberia